In a groundbreaking development that marks a significant milestone in the ongoing battle against metastatic castration-sensitive prostate cancer (mCSPC), a phase 3 trial known as the AMPLITUDE trial has underscored the clinical efficacy of a PARP inhibitor combination therapy. This innovative therapeutic approach, which involves adding niraparib to abiraterone acetate and prednisone, has shown a […]
